PLX - Protalix BioTherapeutics Inc Stock Price, Fair Value and News

1.22USD+0.02 (+1.67%)Market Closed

Market Summary

USD1.22+0.02

Market Closed

1.67%

PLX Stock Price

View Fullscreen

PLX RSI Chart

PLX Valuation

Market Cap

87.7M

Price/Earnings (Trailing)

10.55

Price/Sales (Trailing)

1.34

EV/EBITDA

5.12

Price/Free Cashflow

-35.53

PLX Price/Sales (Trailing)

PLX Profitability

Operating Margin

64.91%

EBT Margin

13.08%

Return on Equity

24.76%

Return on Assets

9.84%

Free Cashflow Yield

-2.81%

PLX Fundamentals

PLX Revenue

Revenue (TTM)

65.5M

Rev. Growth (Yr)

21.69%

Rev. Growth (Qtr)

1.36%

PLX Earnings

Earnings (TTM)

8.3M

Earnings Growth (Yr)

-61.6%

Earnings Growth (Qtr)

-226.35%

Breaking Down PLX Revenue

Last 7 days

5.3%

Last 30 days

-5.5%

Last 90 days

-18.4%

Trailing 12 Months

-50.2%

How does PLX drawdown profile look like?

PLX Financial Health

Current Ratio

1.54

Debt/Equity

0.6

Debt/Cashflow

-0.07

PLX Investor Care

Shares Dilution (1Y)

27.37%

Diluted EPS (TTM)

0.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	41.1M	67.5M	63.6M	65.5M
2022	43.1M	45.4M	47.6M	47.6M
2021	52.6M	48.0M	49.3M	38.4M
2020	65.9M	64.6M	61.2M	62.9M
2019	40.1M	50.4M	64.0M	54.7M
2018	22.7M	18.4M	11.5M	34.2M
2017	11.4M	16.0M	18.9M	21.1M
2016	3.4M	3.8M	7.1M	9.2M
2015	3.7M	3.9M	4.2M	4.4M
2014	13.6M	13.8M	13.9M	3.5M
2013	34.6M	10.7M	9.3M	10.5M
2012	8.1M	33.5M	36.1M	34.9M
2011	9.6M	9.3M	7.2M	8.4M
2010	0	2.5M	4.6M	6.6M
2009	0	0	0	388.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Protalix BioTherapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	bashan dror	acquired	-	-	263,960	president and ceo
Oct 19, 2023	bashan dror	bought	90,483	1.4025	64,516	president and ceo
Aug 15, 2023	rubin eyal	acquired	-	-	201,903	sr. vp and cfo
Aug 15, 2023	naos yaron	acquired	-	-	187,344	sr. vp, operations
Aug 15, 2023	bashan dror	acquired	-	-	800,000	president and ceo
Aug 15, 2023	hayon yael	acquired	-	-	35,115	vp, research & development
Jan 03, 2023	schwartz aharon	bought	155,815	1.4165	110,000	-
Apr 11, 2022	bashan dror	bought	102,000	1.5	68,000	president and ceo
Feb 25, 2022	rubin eyal	acquired	-	-	121,951	sr. vp and cfo
Feb 25, 2022	bashan dror	acquired	-	-	637,531	president and ceo

Which funds bought or sold PLX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.35	-7,000	2,000	-%
Apr 19, 2024	DENALI ADVISORS LLC	sold off	-100	-168,566	-	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	34.00	34.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	7.57	71,693	538,781	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	93.84	192,995	371,934	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	3,738	58,696	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-19,000	-	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	unchanged	-	2,000	29,000	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	added	9.55	144,000	969,000	0.08%

Are Funds Buying or Selling PLX?

Are funds buying PLX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PLX

No. of Funds

Unveiling Protalix BioTherapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 02, 2024	nacht marius	2.9%	2,208,913	SC 13G/A
Jan 03, 2023	nacht marius	5.3%	2,816,901	SC 13G/A
Jun 09, 2022	whitebox advisors llc	5.65%	2,816,108	SC 13G
Feb 14, 2022	highbridge capital management llc	5.03%	2,414,487	SC 13G/A
Feb 11, 2022	highbridge capital management llc	0%	0	SC 13G/A
Jan 31, 2022	nacht marius	5.8%	2,816,901	SC 13G/A
Jul 30, 2021	burrage capital management llc	0%	0	SC 13G/A
Jun 15, 2021	dexcel pharma technologies ltd.	4.47%	2,034,117	SC 13G/A
Feb 16, 2021	ubs oconnor llc	3.2%	1,091,176	SC 13G/A
Feb 16, 2021	dexcel pharma technologies ltd.	10.30%	4,556,031	SC 13G/A

Recent SEC filings of Protalix BioTherapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 03, 2024	4	Insider Trading
Mar 14, 2024	8-K	Current Report
Mar 14, 2024	10-K	Annual Report

Peers (Alternatives to Protalix BioTherapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Protalix BioTherapeutics Inc News

Latest updates

Protalix BioTherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	1.4%	10,486,000	10,345,000	35,075,000	9,588,000	8,617,000	14,183,000	8,753,000	16,085,000	8,549,000	12,054,000	6,427,000	11,320,000	19,495,000	10,790,000	10,967,000	21,646,000	17,759,000	14,248,000	12,247,000	10,439,000	27,018,000
Cost Of Revenue	81.0%	8,856,000	4,893,000	6,148,000	3,085,000	2,397,000	7,074,000	4,087,000	6,034,000	3,148,000	3,703,000	4,733,000	4,765,000	2,752,000	2,868,000	1,827,000	3,426,000	2,950,000	3,205,000	2,695,000	2,045,000	2,278,000
S&GA Expenses	12.9%	4,143,000	3,670,000	4,031,000	3,115,000	3,098,000	2,848,000	2,611,000	3,154,000	3,466,000	2,954,000	3,171,000	3,138,000	2,951,000	2,816,000	2,194,000	3,187,000	3,014,000	2,587,000	2,068,000	2,230,000	2,172,000
R&D Expenses	-15.5%	3,102,000	3,669,000	4,475,000	5,847,000	5,617,000	7,386,000	7,579,000	8,767,000	7,641,000	7,282,000	7,689,000	7,122,000	10,953,000	7,688,000	9,186,000	10,340,000	9,595,000	10,000,000	13,323,000	11,698,000	9,036,000
EBITDA Margin	-22.6%	0.19	0.25	0.21	-0.29	-0.23	-0.51	-0.53	-0.54	-0.60	-0.02	-0.02	-0.02	-	-	-	-	-	-	-	-	-
Interest Expenses	-100.1%	-1,000	766,000	899,000	1,078,000	-	1,078,000	-	1,120,000	122,000	1,116,000	-	-	2,172,000	-	-	-	2,172,000	-	-	-	2,174,000
Income Taxes	-387.2%	-382,000	133,000	308,000	195,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-273.8%	-6,426,000	-1,719,000	19,647,000	-2,936,000	-3,210,000	-3,567,000	-5,334,000	-2,286,000	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-29.4%	0.13	0.19	0.15	-0.37	-0.30	-0.58	-0.61	-0.64	-0.72	-0.13	-0.14	-0.12	-	-	-	-	-	-	-	-	-
Net Income	-226.3%	-6,044,000	-1,852,000	19,339,000	-3,131,000	-3,740,000	-3,567,000	-5,334,000	-2,286,000	-6,667,000	-4,199,000	-11,241,000	-5,475,000	397,000	-4,437,000	-4,150,000	1,667,000	291,000	-3,560,000	-7,743,000	-7,264,000	-5,434,000
Net Income Margin	-23.9%	0.13	0.17	0.13	-0.38	-0.31	-0.38	-0.41	-0.57	-0.72	-0.42	-0.43	-0.26	-	-	-	-	-	-	-	-	-
Free Cashflow	145.6%	3,345,000	-7,335,000	4,769,000	-3,246,000	-2,824,000	-9,262,000	-7,484,000	-6,058,000	-5,535,000	-2,224,000	6,235,000	-10,220,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-3.6%	84.00	88.00	88.00	67.00	56.00	57.00	61.00	68.00	74.00	83.00	108	103	68.00	72.00	72.00	83.00	45.00	54.00	55.00	61.00	61.00
Current Assets	-3.7%	70.00	73.00	74.00	55.00	45.00	46.00	50.00	57.00	62.00	71.00	96.00	91.00	56.00	60.00	54.00	58.00	32.00	40.00	42.00	47.00	53.00
Cash Equivalents	15.8%	24.00	20.00	48.00	33.00	17.00	11.00	12.00	17.00	39.00	11.00	34.00	20.00	18.00	14.00	5.00	14.00	18.00	21.00	25.00	30.00	38.00
Inventory	-11.8%	19.00	22.00	20.00	20.00	17.00	15.00	17.00	17.00	18.00	15.00	14.00	14.00	13.00	13.00	11.00	9.00	8.00	8.00	7.00	7.00	9.00
Net PPE	6.2%	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	6.00	6.00	6.00	6.00
Liabilities	3.1%	51.00	49.00	49.00	66.00	66.00	68.00	71.00	76.00	80.00	83.00	104	88.00	95.00	106	106	114	116	125	123	121	114
Current Liabilities	5.0%	46.00	43.00	23.00	32.00	32.00	34.00	31.00	35.00	33.00	43.00	96.00	81.00	86.00	44.00	42.00	48.00	40.00	33.00	26.00	27.00	25.00
Long Term Debt	-	-	-	20.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	-	-	-	54.00	53.00	52.00	51.00	50.00	49.00	49.00	48.00
LT Debt, Current	0.3%	20.00	20.00	-	-	-	-	-	-	-	3.00	56.00	55.00	54.00	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	20.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	-	-	-	54.00	53.00	52.00	51.00	50.00	49.00	49.00	48.00
Shareholder's Equity	-12.2%	34.00	38.00	39.00	1.00	-10.64	-	-	-	-6.04	0.00	4.00	15.00	-27.04	-	-	-	-	-	-	-	-
Retained Earnings	-Infinity%	-381	-	-	-	-389	-	-	-	-374	-	-	-	-347	-	-	-	-340	-	-	-	-322
Additional Paid-In Capital	-	415	-	-	-	379	-	-	-	369	-	-	-	320	-	-	-	270	-	-	-	270
Shares Outstanding	10.9%	73.00	66.00	67.00	57.00	54.00	49.00	47.00	46.00	44.00	46.00	43.00	40.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	139	-	-	-	52.00	-	-	-	85.00	-	-	-	121	-	-	-	68.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	152.2%	3,595	-6,888	4,973	-2,998	-2,611	-9,204	-7,356	-5,829	-5,087	-1,880	6,516	-9,834	-7,550	-3,604	-7,835	-7,117	-3,687	-3,225	-5,170	-7,276	-4,004
Share Based Compensation	24.6%	1,367	1,097	438	546	539	422	288	836	418	563	578	816	1,014	1,414	267	431	236	196	113	290	418
Cashflow From Investing	98.4%	-342	-20,879	-222	4,732	4,953	5,912	357	-16,257	37,436	4,629	7,540	-30,684	7,592	7,803	-268	-35,079	29.00	-446	-95.00	-371	84.00
Cashflow From Financing	-	-	-	10,433	14,233	4,075	1,520	-	-	-4,046	-25,990	-	42,114	4,652	4,472	-1,264	38,607	-	-	-	-	-

PLX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
TOTAL REVENUE	$ 65,494	$ 47,638	$ 38,350
COST OF GOODS SOLD	(22,982)	(19,592)	(16,349)
RESEARCH AND DEVELOPMENT EXPENSES	(17,093)	(29,349)	(29,734)
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	(14,959)	(11,711)	(12,729)
OPERATING INCOME (LOSS)	10,460	(13,014)	(20,462)
FINANCIAL EXPENSES	(3,180)	(2,529)	(7,521)
FINANCIAL INCOME	1,286	1,146	401
FINANCIAL EXPENSES, NET	(1,894)	(1,383)	(7,120)
INCOME (LOSS) BEFORE TAXES ON INCOME	8,566	(14,397)	(27,582)
TAXES ON INCOME	(254)	(530)
NET INCOME (LOSS) FOR THE PERIOD	$ 8,312	$ (14,927)	$ (27,582)
EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC	$ 0.12	$ (0.31)	$ (0.62)
EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED	$ 0.09	$ (0.31)	$ (0.62)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- BASIC	67,512,527	48,472,159	44,140,233
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- DILUTED	82,424,016	48,472,159	44,140,233
Goods
TOTAL REVENUE	$ 40,418	$ 25,292	$ 16,749
License and R&D Services
TOTAL REVENUE	$ 25,076	$ 22,346	$ 21,601

PLX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 23,634	$ 17,111
Short-term bank deposits	20,926	5,069
Accounts receivable - Trade	5,272	4,586
Other assets	1,055	1,310
Inventories	19,045	16,804
Total current assets	69,932	44,880
NON-CURRENT ASSETS:
Funds in respect of employee rights upon retirement	528	1,267
Property and equipment, net	4,973	4,553
Deferred income tax asset	3,092	0
Operating lease right of use assets	5,909	5,087
Total assets	84,434	55,787
Accounts payable and accruals:
Trade	4,320	5,862
Other	19,550	12,271
Operating lease liabilities	1,409	1,118
Contracts liability	0	13,178
Convertible notes	20,251	0
Total current liabilities	45,530	32,429
LONG TERM LIABILITIES:
Convertible notes		28,187
Liability for employee rights upon retirement	714	1,642
Operating lease liabilities	4,621	4,169
Total long term liabilities	5,335	33,998
Total liabilities	50,865	66,427
COMMITMENTS
STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)
Common Stock, $0.001 par value: Authorized - as of December 31, 2022 and 2023, 144,000,000 and 185,000,000 shares, respectively; issued and outstanding - as of December 31, 2022 and 2023, 53,790,167 and 72,952,124 shares, respectively	73	54
Additional paid-in capital	415,045	379,167
Accumulated deficit	(381,549)	(389,861)
Total stockholders' equity (capital deficiency)	33,569	(10,640)
Total liabilities and stockholders' equity (net of capital deficiency)	$ 84,434	$ 55,787

About Protalix BioTherapeutics Inc

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; FundaÃƒÂ§ÃƒÂ£o Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

CEO	Mr. Dror Bashan
WEBSITE	protalix.com
INDUSTRY	Biotechnology
EMPLOYEES	193

Protalix BioTherapeutics Inc Frequently Asked Questions

What is the ticker symbol for Protalix BioTherapeutics Inc? What does PLX stand for in stocks?

PLX is the stock ticker symbol of Protalix BioTherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Protalix BioTherapeutics Inc (PLX)?

As of Tue Apr 23 2024, market cap of Protalix BioTherapeutics Inc is 87.66 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PLX stock?

You can check PLX's fair value in chart for subscribers.

What is the fair value of PLX stock?

You can check PLX's fair value in chart for subscribers. The fair value of Protalix BioTherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Protalix BioTherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PLX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Protalix BioTherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PLX is over valued or under valued. Whether Protalix BioTherapeutics Inc is cheap or expensive depends on the assumptions which impact Protalix BioTherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PLX.

What is Protalix BioTherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, PLX's PE ratio (Price to Earnings) is 10.55 and Price to Sales (PS) ratio is 1.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PLX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Protalix BioTherapeutics Inc's stock?

In the past 10 years, Protalix BioTherapeutics Inc has provided -0.296 (multiply by 100 for percentage) rate of return.